Difference between revisions of "Kenneth Hillan"
(Created page with "Kenneth Hillan ==Country== United States ==Birth - Death== ==Occupation== Business, Medicine ==Description== Former Chief...") |
|||
| Line 1: | Line 1: | ||
| − | [[File: | + | [[File:kennethhillan.jpg|200px|thumb|left|Kenneth Hillan]] |
==Country== | ==Country== | ||
| Line 15: | Line 15: | ||
Former Chief Therapeutics Officer, 23andMe (consumer genetics and research company) from 2019 to 2023. President of Research & Development at Archaogen (2011-2018). Served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in China. | Former Chief Therapeutics Officer, 23andMe (consumer genetics and research company) from 2019 to 2023. President of Research & Development at Archaogen (2011-2018). Served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in China. | ||
| + | |||
| + | ==See Also== | ||
| + | |||
| + | * [[LGBTQ Participants in Pharmaceutical, Vaccine and Biotech Studies]] | ||
==Further Reading/Research== | ==Further Reading/Research== | ||
Latest revision as of 01:02, 2 October 2023
Country
United States
Birth - Death
Occupation
Business, Medicine
Description
Former Chief Therapeutics Officer, 23andMe (consumer genetics and research company) from 2019 to 2023. President of Research & Development at Archaogen (2011-2018). Served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in China.